Table 2 Difference in clinical characters between native liver survivors and other subjects in this hepatoblastoma cohort
From: Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma
Survive with Native liver (n = 22) | Others (n = 9) | p-value | |
|---|---|---|---|
Diagnostic age, medium (range), years | 1 (0–10.0) | 2 (1–15.0) | 0.004 |
Male gender, n (%) | 15 (68.2) | 4 (44.4%) | 0.25 |
Initial maximal tumor diameter, medium (range), cm | 9.50 (4.20–20.1) | 9.90 (5.0–13.0) | 0.78 |
Initial AFP level, medium (range), log10 ng/mL | 5.23 (3.33–6.16) | 5.09 (1.30–6.47) | 0.84 |
Maximal tumor size after neo-adjuvant chemotherapy, medium (range), cm | 5.00 (2.6–11.0) | 7.40 (1.50–12.0) | 0.31 |
AFP level after neo-adjuvant chemotherapy, medium (range), log10 ng/mL | 2.01 (1.15–4.58) | 3.44 (1.18–6.55) | 0.04 |
PRETEXT stage*, n (%) | |||
PRETEXT I | 1 (4.55%) | 0 (0%) | |
PRETEXT II | 10 (45.45%) | 3 (33.33%) | |
PRETEXT III | 7 (31.82%) | 3 (33.33%) | |
PRETEXT IV | 4 (18.18%) | 3 (33.33%) | 0.73 |